Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

Lehnert, Martina; Ludwig, H; Zojer, Niklas

doi:10.2147/ott.s3975

Cited by 6 publications

(2 citation statements)

References 54 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yttrium ibritumomab tiuxetan ( 90 Y-IT) or ZEVAKIN® contains a radioactive substance called Yttrium-90 ( 90 Y) to treat certain types of B-cell non-Hodgkin lymphoma (NHL) or previously untreated follicular NHL who get a partial or complete response to first-line chemotherapy. Yttrium-90 emits beta particles (2.28 MeV) with a physical half-life of 64.1 hours (2.67 days) [83,87].…”

Section: Radiopharmaceuticals Approved By Food and Drug Administrationmentioning

confidence: 99%

Advances in Radiotherapy Dosimetry Techniques and Pre-Treatment Verification

Salari,

Ishmael Parsai

2023

Advances in Dosimetry and New Trends in Radiopharmaceuticals

View full text Add to dashboard Cite

In the fight against cancer, radiation therapy plays a vital role, with its two essential approaches: internal, involving the insertion or implantation of radioactive material into the patient’s body, or uptake of radiopharmaceutical, and external. Precise delivery of the appropriate radiation dosage to the tumor is critical for achieving favorable outcomes. This is where dosimetry becomes crucial—a scientific discipline that involves measuring, calculating, and evaluating radiation doses. Medical physicists utilize dosimetry to ensure the accuracy and proper calibration of machines that administer ionizing radiation, ensuring safety. This chapter provides a brief overview of advanced techniques and equipment used in dosimetry, with a primary focus on photon and electron dosimetry, the most widely employed forms of radiation for radiotherapy worldwide.

show abstract

Section: Radiopharmaceuticals Approved By Food and Drug Administrationmentioning

confidence: 99%

Advances in Radiotherapy Dosimetry Techniques and Pre-Treatment Verification

Salari,

Ishmael Parsai

2023

Advances in Dosimetry and New Trends in Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…90 Y emits beta particles, which penetrate soft tissue to a relatively long spatial depth of 5.3 mm. Therefore, 90 Y-labeled mAbs cause DNA damage to the targeted cells as well as to adjacent or more distant cells due to their long range [ 19 ]. As a result of this cross-fire effect, there is an expectation that FF-21101( 90 Y) will have a more positive therapeutic impact on treating solid tumors than anti-CDH3 therapies alone, making 90 Y ideal for this purpose [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates

Ravizzini,

Erwin,

De Palatis

et al. 2023

Cancers

View full text Add to dashboard Cite

P-cadherin is associated with a wide range of tumor types, making it an attractive therapeutic target. FF-21101 is a human–mouse chimeric monoclonal antibody (mAb) directed against human P-cadherin, which has been radioconjugated with indium-111 (111In) utilizing a DOTA chelator. We investigated the biodistribution of FF-21101(111In) in cynomolgus macaques and extrapolated the results to estimate internal radiation doses of 111In- and yttrium-90 (90Y)-FF-21101 for targeted radioimmunotherapy in humans. Whole-body planar and SPECT imaging were performed at 0, 2, 24, 48, 72, 96, and 120 h post-injection, using a dual-head gamma camera. Volumes of interest of identifiable source organs of radioactivity were defined on aligned reference CT and serial SPECT images. Organs with the highest estimated dose values (mSv/MBq) for FF-21101(111In) were the lungs (0.840), spleen (0.816), liver (0.751), kidneys (0.629), and heart wall (0.451); and for FF-21101(90Y) dose values were: lungs (10.49), spleen (8.21), kidneys (5.92), liver (5.46), and heart wall (2.61). FF-21101(111In) exhibits favorable biodistribution in cynomolgus macaques and estimated human dosimetric characteristics. Data obtained in this study were used to support the filing of an investigational new drug application with the FDA for a Phase I clinical trial.

show abstract